Trexquant Investment LP Beam Therapeutics Inc. Transaction History

Trexquant Investment LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$23.01 - $32.46 $344,045 - $485,341	14,952 New	14,952 $359,000
Q1 2023 May 15, 2023	BUY	$30.15 - $48.79 $91,203 - $147,589	3,025 Added 58.86%	8,164 $249,000
Q4 2022 Feb 13, 2023	SELL	$36.73 - $51.6 $627,899 - $882,102	-17,095 Reduced 76.89%	5,139 $200,000
Q3 2022 Nov 14, 2022	SELL	$39.79 - $70.31 $1.41 Million - $2.49 Million	-35,443 Reduced 61.45%	22,234 $1.06 Million
Q2 2022 Aug 11, 2022	BUY	$29.86 - $62.36 $1.08 Million - $2.25 Million	36,050 Added 166.69%	57,677 $2.23 Million
Q1 2022 May 13, 2022	BUY	$53.73 - $82.16 $1.16 Million - $1.78 Million	21,627 New	21,627 $1.24 Million
Q4 2021 Feb 14, 2022	SELL	$68.02 - $99.06 $938,880 - $1.37 Million	-13,803 Closed	0 $0
Q3 2021 Nov 12, 2021	BUY	$84.37 - $133.6 $612,441 - $969,802	7,259 Added 110.93%	13,803 $1.2 Million
Q2 2021 Aug 12, 2021	SELL	$64.12 - $128.71 $726,736 - $1.46 Million	-11,334 Reduced 63.4%	6,544 $842,000
Q1 2021 May 13, 2021	BUY	$71.28 - $120.75 $656,417 - $1.11 Million	9,209 Added 106.23%	17,878 $1.43 Million
Q4 2020 Feb 11, 2021	BUY	$22.24 - $95.63 $192,798 - $829,016	8,669 New	8,669 $708,000

236

75.2M

438K

232K

Ticker BEAM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,354,600
Market Cap $1.78B
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.